BUZZ - UBS raises AbbVie’s target price, citing expansion of its core business beyond the immunology drug sector
路透社2026/10/09 15:01On October 9, UBS raised its target price for AbbVie (ABBV.N) from $260 to $275, stating that investors' focus is shifting from blockbuster drugs Skyrizi and Rinvoq to the next wave of growth in its immunology business. UBS also noted that other projects in AbbVie’s R&D pipeline remain robust. It expects strong third-quarter performances from Skyrizi and Rinvoq, with respective sales reaching $5.7 billion and $2.7 billion. Special attention was given to upcoming combined treatment data of Skyrizi for Crohn's disease and ulcerative colitis, with mid-stage trial results to be released later this month. UBS believes that the drug lutikizumab, for inflammatory skin diseases, has a potential market size of $1-2 billion, and pointed out that Rinvoq sales are likely to surpass $500 million. The report also mentioned positive late-stage clinical data for cancer drugs Epkinly and etentamig, as well as the recent launch of the Parkinson’s disease medication tavapadon. UBS expects third-quarter earnings per share (EPS) to reach $3.76, within AbbVie’s forecast range of $3.73 to $3.77. Including intraday fluctuations, AbbVie’s stock has risen 21% so far this year. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. Due to potential inaccuracies or lack of required context in automated translations, Reuters does not guarantee the accuracy of these texts and is not liable for any damage or loss arising from their use. The translations are provided solely for readers' convenience.)
October 9 - ** UBS raises AbbVie (ABBV.N) price target from $260 to $275
** States that investor focus is shifting from blockbuster drugs Skyrizi and Rinvoq to the next wave of growth in the immunology business; notes that other projects in the R&D pipeline continue to show strong momentum
** Expects Skyrizi and Rinvoq to perform strongly in the third quarter, with sales projected to reach $5.7 billion and $2.7 billion, respectively
** Highlights upcoming data on Skyrizi's use in the combined treatment of Crohn's disease and ulcerative colitis, with mid-term trial results to be released later this month
** Believes that the drug lutikizumab for treating inflammatory skin diseases has a potential market size of $1 billion to $2 billion; points out that Rinvoq sales are likely to exceed $500 million
** Mentions positive late-stage clinical data for the cancer drugs Epkinly (link) and etentamig, as well as the recent launch of the Parkinson's disease treatment tavapadon (link)
** Expects third-quarter earnings per share (EPS) of $3.76, within AbbVie's forecast range of $3.73 to $3.77
** Including intraday fluctuations, the stock has risen 21% since the beginning of the year
(To facilitate non-English speakers, Reuters automates the translation of its reports into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of the translated text, which is provided solely for reader convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Update: Equities Rise Intraday as Traders Parse Consumer Sentiment Survey
01:37 PM EDT, 10/09/2026 (MT Newswires) -- (Updates with latest market prices and developments.) US benchmark equity indexes were higher intraday as investors evaluated a survey on consumer sentiment. The Dow Jones Industrial Average was up 0.8% at 51,628.8 after midday Friday, while the Nasdaq Composite and the S&P 500 rose 0.6% each to 27,352.4 and 7,809.5, respectively. Barring communication services, all sectors were in the green, led by real estate. US consumer sentiment fell in October as the one- and five-year inflation expectations reached their highest levels since May, preliminary results of a University of Michigan survey showed Friday. "While year-ahead expectations for personal finances and business conditions crept up slightly, buying conditions for durables plummeted amid high prices and borrowing costs," Surveys of Consumers Director Joanne Hsu said. "Frustration over cost-of-living continues to mount, as consumers across the political spectrum believe that the trajectory of the economy has weakened since the beginning of the year." Markets are currently pricing in a nearly 81% probability that the Federal Reserve will keep its benchmark rate steady later this month, with the remaining odds in favor of a second consecutive 25-basis-point hike, as the central bank looks to tame inflation, according to the CME FedWatch tool. West Texas Intermediate crude was down 0.4% at $91.17 a barrel intraday, while Brent lost 0.5% to $103.81. The 10-year US Treasury yield was up 1.5 basis points at 5.25%, while the two-year rate increased 3.9 basis points to 4.8%. In company news, SpaceX (SPCX) shares were up 0.5%. The rocket and satellite company said late Thursday it agreed to acquire a nationwide low-band spectrum portfolio from investment firm Grain Management as it seeks to establish Starlink Mobile as a major US mobile carrier. T-Mobile US (TMUS) shares sank 13% intraday Friday, the worst performer on the S&P 500, followed by AT&T (T) and Verizon Communications (VZ), which fell 10% and 9.8%, respectively.
Ameren declares quarterly dividend of $0.75 a share
Ameren declared a quarterly cash dividend of 75 cents per common share. Dividend payable Dec. 31, 2026. Shareholders of record as of Dec. 8, 2026 will receive the dividend. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ameren Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610091331PR_NEWS_USPR_____CG68019) on October 09, 2026, and is solely responsible for the information contained therein.
McEwen’s $55M Ontario asset sale fuels gold growth plans
US Stock Market Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuts on the US stock market; shares fall over 10% after opening
As of press time, the stock has dropped more than 10%, trading at $10.77.
Crypto prices
More
